Skip to main content
. 2015 Jan 28;10(12):2171–2192. doi: 10.4161/auto.36436

Figure 7.

Figure 7.

Neuronal loss paralleled by astro- and microgliosis in transgenic mice, by BafA1 treatment. Immunohistochemical assessment of neuronal loss and astrogliosis paralleled by a microgliosis. (A) Representative images of RBFOX3/NeuN+ neurons, GFAP+ astroglia and the microglial marker AIF1 in the hippocampus of SNCA-tg and non-tg mice treated with BafA1 or vehicle. The insets in the 1st row depict the region of quantification. Insets in the 2nd row depict regions which are magnified in the 3rd row. Scale bar for RBFOX3/NeuN in the hippocampus 50 μm, GFAP in the hippocampus 50 μm and 20 μm (2nd and 3rd row) and AIF1 in the hippocampus and the neocortex 20 μm (4th and 5th row). Quantification of cell number and optical density quantification of (B) the neuronal marker RBFOX3/NeuN+, (C) the astroglial marker GFAP, (D) the microglial marker AIF1 in the hippocampus, and (E) AIF1 in the neocortex of SNCA-tg mice compared to non-tg mice. (B) to (E) Effects of BafA1 treatment in the hippocampus of SNCA-tg mice compared to vehicle treatment. All values are mean + s.e.m; differences are significant at (#) P < 0.05, unpaired t test, and at (*) P < 0.01.